The susceptibilities of a range of gram-positive and gram-negative microbial pathogens to clofazimine and its analog B669 (0.1 to 32 pg/ml), as well as the effects of these agents on membrane phospholipid metabolism in Staphylococcus aureus and Escherichia coli, have been investigated in vitro. Gram-positive bacteria were found to be generally susceptible to these agents, whereas gram-negative organisms were uniformly resistant. Exposure of S. aureus to both agents (1 to 5 ,ug/ml), especially B669, caused dose-related enhancement of the activity of phospholipase A2, according to an increase in the release of 3H-radiolabeled arachidonate and lysophosphatidylethanolamine ( 
The antimycobacterial riminophenazine agent clofazimine, which was first described in 1957 (5) , is one of the standard drugs for the treatment of leprosy (4, 9, 14, 21) and is now recommended as part of a combination therapy for this disease (22) . It is also useful in the antimicrobialcombination chemotherapy of Mycobacterium avium infections in AIDS patients (1) . Clofazimine also inhibits the growth of tubercle bacilli in vitro and in animal models of experimental infection (7) .
Although clofazimine was described in 1957, the biochemical mechanism of its antimicrobial activity has not been established. As a consequence of its highly lipophilic nature and redox potential (-0.18 V at pH 7) , it has been proposed that intracellular generation of hydrogen peroxide by redoxcycling mechanisms may contribute to the antimicrobial activity of clofazimine (5) . It has also been reported that clofazimine binds to the guanine bases of DNA, thereby blocking the template function of the DNA, leading to inhibition of proliferation (17) . The increase in the guanine and cytosine content of microbial DNA relative to that of human DNA may explain the selective inhibitory effects of clofazimine on the proliferation of microbial cells (5) .
In the present study, we have investigated the antimicrobial spectrum of clofazimine and its analog B669 (6, 19) , as well as the biochemical mechanism of the antimicrobial activities of these agents. B669 was included for comparison on the basis of preliminary screening experiments which indicated that it possessed superior antimicrobial activity, relative to that of clofazimine, for some microbial pathogens. Our data demonstrate that these riminophenazines are broadly active against gram-positive bacteria, whereas gramnegative microorganisms are uniformly resistant. Moreover, antiproliferative lysophospholipids generated in the cell membrane of gram-positive bacteria during exposure to 10-phenyl-2,10-dihydro-2-(cyclohexylimino)-phenazine] are diagrammed in Fig. 1 . Both agents were synthesized by J. F. O'Sullivan and dissolved in dimethyl sulfoxide (DMSO) to give stock concentrations of 2 mg/ml. Subsequent dilutions were made in sterile, distilled water, and both agents were used at final concentrations ranging from 0.1 to 32 ,tg/ml.
Appropriate solvent controls were included in the various assays described below.
Chemicals, reagents, and enzymes. Unless otherwise indicated, chemicals, reagents, and enzymes were obtained from the Sigma Chemical Co. (St. Louis, Mo.), and radiochemicals were obtained from Du Pont-NEN Research Products (Boston, Mass.) and Amersham International (Aylesbury, United Kingdom).
Microbial pathogens. The various microbial pathogens and their origins (reference strain or clinical isolate) are listed in Table 1 .
MICs and MBCs. The MICs and MBCs of clofazimine and B669 for the various test microbial pathogens were determined by standard bacteriological assays (18) broth) and anaerobic (with a prereduced, supplemented brain heart infusion broth) conditions. Protection experiments with antioidative agents. The potential of various lipid and water-soluble antioxidant chemicals and enzymes (dl-a-tocopherol, dl-a-tocopherol acetate, retinol, retinol acetate, butylated hydroxyanisole, ascorbic acid, dithiothreitol, desferrioxamine, catalase, and superoxide dismutase at final concentrations of 25 ,ug/ml, 25 ,g/ml, 5 p,g/ml, 50 p,g/ml, 10 p,g/ml, 100 p.g/ml, 100 pg/ml, 100 pg/ml, 500 U/ml and 200 U/ml, respectively) to protect S. aureus ATCC 25923 or Staphylococcus epidennidis ATCC 2223 against riminophenazine-mediated inhibition of bacterial growth was investigated by a sensitive radioassay based on the uptake of added radiolabeled amino acids by proliferating bacteria. At the predetermined concentrations listed above, none of the test agents per se (i.e., in the absence of the riminophenazines) either inhibited or incorporation of this unsaturated fatty acid into bacterial phospholipid, almost exclusively into phosphatidylethanolamine (PE). This is in agreement with a previous report (10) . The bacteria were then preincubated for 5 min at 37C prior to the addition of the riminophenazines. After the addition of the test agents, the final volume in each tube was 2 ml and contained 2 x 109 bacteria. The tubes were incubated for 120 min (predetermined in preliminary experiments), and the reactions were terminated by the addition of 5 ml of n-hexane-isopropanol-concentrated HCI (final concentration, 0.1 M [300:200:4; vol/voltvol]). Fatty acids were extracted as described previously (20 coli were measured by a previously described high-performance TLC (HPTLC) method (8) . The bacteria were inoculated into 10 ml of nutrient broth containing 50 pCi of radiolabeled palmitate {[9,10-3H(N)]; specific activity, 60
Ci/mmol; Du Pont-NEN} per ml, and the mixtures were incubated for 4 h (predetermined in preliminary experiments) at 37°C to allow incorporation of the radiolabeled saturated fatty acid into the C-1 position of the glycerol backbone of membrane phospholipids. In a series of preliminary experiments, it was established that after coincubation 20 ,ug/ml) were investigated by the radioassay.
Test bacteria were inoculated into nutrient broth containing 0.25 pCi of radiolabeled amino acids with and without the lysophospholipids, and the mixtures were incubated for 6 h at 37C, after which bacterial growth was assessed according to the uptake of radiolabeled amino acids. In an additional series of experiments, S. aureus ATCC 25923 and S. epidermidis ATCC 2223 were exposed to the lysophospholipids (0.5 to 20 pg/ml) in the presence and absence of a-tocopherol (25 jg/ml).
Protection experiments with lysophospholipase. The potential of added, purified lysophospholipase (2-lysophosphatidylcholine acylhydrolase-phospholipase B from Vibrio species) to protect S. aureus ATCC 25923 against clofazimineand B669-mediated inhibition of bacterial growth was investigated by the radioassay described above, which is based on the uptake of radiolabeled amino acids by proliferating bacteria. Nutrient broth containing 0.25 pCi of radiolabeled amino acids, with and without 200 mU of lysophospholipase per ml, was inoculated with S. aureus, and the tubes were incubated for 15 min at 37°C, after which a sub-MIC concentration (0.5 pg/ml) of clofazimine or B669 or solvent controls was added. The tubes were then incubated at 37TC, and fresh lysophospholipase (200 mU) was added to enzyme-containing tubes after 2 and 4 h, with appropriate volume adjustments made for enzyme-free control tubes. After 6 and 18 h of incubation at 37°C, bacterial growth was Measurement of possible complex formation ofce-tocopherol with dofazimine and B669. The UV absorption spectra of mixtures of a-tocopherol (up to 100 ag/ml) and clofazimine or B669 (up to 10 p,g/ml) in ethanol relative to identical concentrations of the individual agents were measured as described previously (13) 32 pg/ml. Anaerobiosis increased the susceptibility of the facultative anaerobes S. aureus and S. pyogenes to the riminophenazines as well as the susceptibility of E. faecalis to clofazimine ( Table 1) .
Measurement of the protective potential of antioxidative agents. Of the various agents tested, only a-tocopherol protected S. aureus and S. epidennidis against the antiproliferative effects of both clofazimine and B669. The effects of a-tocopherol (25 p,g/ml) on the growth of S. aureus coincubated with clofazimine or B669 at 0.5 pg/ml are shown in Table 2 . a-Tocopherol also protected M. tuberculosis against the inhibitory effects of the riminophenazines (0.25 to 5 ,ug/ml); these data are shown in Fig. 2 .
Retrospective addition of a-tocopherol to S. aureus, which had been exposed to B669 (2 tg/ml) during the preceding 18 h, caused reactivation of bacterial growth as measured by the radioassay with an 18-h reincubation period. The level of uptake of radiolabeled amino acids by B669-pretreated (18 h), a-tocopherol-free bacteria was 12.3 + 9.5 cpm, in comparison with a value of 1,383.3 ± 31.1 cpm in the corresponding a-tocopherol-treated system. The levels of uptake of radiolabeled amino acids by a riminophenazine-free control system without and with a-tocopherol were 1,352 ± 22.4 cpm and 1,637.7 ± 43.5 cpm, respectively. These data demonstrate that a-tocopherol also reverses riminophenazine-mediated inhibition of bacterial growth.
Bacterial PLA2 activity. The effects of the riminophenazines (1, 2.5, and 5 Ftg/ml) on the activity of PLA2 in S. Effects of lysophospholipase on clofazimine-and B669-mediated inhibition of the growth of S. aureus. Data for the effects of lysophospholipase on rimiophenazine-mediated inhibition of the growth of S. aureus are shown in Table 5 . After 6 h of incubation, only trivial growth was observed in the clofazimine-or B669-containing systems with and without lysophospholipase (data not shown). After extended incubation (18 h), however, lysophospholipase treatment was found to confer partial but significant protection against riminophenazine-mediated inhibition of the growth of S. aureus. (19a) . In the present study, the effects of clofazimine and B669 on the PLA2 activities of S. aureus and E. coli were measured according to the extent of release of the primary enzymatic hydrolysis products, unsaturated fatty acid and lysophospholipid (11 (Table 5) . Lysophospholipase-mediated protection was delayed and manifested as a slow recovery of bacterial growth. This is probably due to the rapid effects of the riminophenazines on PLA2 activity, as well as restricted access of the enzyme to the lysophospholipids, leading to a gradual neutralization of these agents. The protective effects of lysophospholipase are the most compelling evidence implicating lysophospholipids as the primary mediators of the antimicrobial activities of clofazimine and B669. The mechanism of riminophenazine resistance operative in all of the species of gram-negative bacteria tested in this study remains unestablished but does not appear to be due to increased lysophospholipase activity. The activities of purified PTA2 and lysophospholipase were unaffected by either clofazimine or B669 (5 ,ug/ml).
These observations demonstrate that the riminophenazines do not appear to act directly on either enzyme. In the bacterial-cell membrane, these highly lipophilic riminophenazines may disrupt membrane structure, making the integral phospholipids more susceptible to attack by PIA2.
In conclusion, the biochemical mechanism of the antimicrobial activities of clofazimine and its analog B669 is related to an increase in the activity of bacterial PLA2, leading to release and accumulation of lysophospholipids. These agents possess selective antimicrobial activities against gram-positive bacteria.
